Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IH Stock Summary
Top 10 Correlated ETFs
IH
In the News

iHuman Clocks 105% Growth In Q2 Revenue
iHuman Inc (NYSE: IH) reported second-quarter FY21 revenue growth of 105.9% year-on-year, to RMB221.3 million ($34.3 million). Revenues from online subscriptions rose 110.1% Y/Y to RMB199.2 million ($30.9 million).

iHuman Inc. Announces Second Quarter 2021 Unaudited Financial Results
BEIJING, Sept. 29, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered smart learning products in China, today announced its unaudited financial results for the second quarter ended June 30, 2021.

iHuman Inc. (IH) CEO Dr. Peng Dai on Q1 2021 Results - Earnings Call Transcript
iHuman Inc. (IH) CEO Dr. Peng Dai on Q1 2021 Results - Earnings Call Transcript

iHuman Inc. Announces First Quarter 2021 Unaudited Financial Results
BEIJING, June 8, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("Human" or the "Company"), a leading childhood edutainment company in China, today announced its unaudited financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Total revenues were RMB226.7 million (US$34.6 million), a year-over-year increase of 190.6%.

iHuman Inc. to Report First Quarter 2021 Unaudited Financial Results on June 8, 2021
BEIJING, June 3, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading childhood edutainment company in China, announced today that it will report its unaudited financial results for the first quarter ended March 31, 2021, before U.S. markets open on June 8, 2021. The Company's management will hold an earnings conference call on Tuesday, June 8, 2021 at 8:00 a.m.

iHuman Inc. Files 2020 Annual Report on Form 20-F
BEIJING, China, April 28, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading childhood edutainment company in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission on April 28, 2021. The annual report on Form 20-F is available on the Company's investor relations website at https://ir.ihuman.com/.

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results
BEIJING, March 25, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading childhood edutainment company in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter 2020 Highlights Total revenues were RMB189.5 million (US$29.0 million), a year-over-year increase of 206.4%.

iHuman Inc. to Report Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 25, 2021
BEIJING, March 19, 2021 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading childhood edutainment company in China, announced today that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020, before U.S. markets open on March 25, 2021. The Company's management will hold an earnings conference call on Thursday, March 25, 2021 at 8:00 a.m.

iHuman: Clear Leader In Child Edutainment In China
iHuman became #1 in the market in 4 years with no marketing spend purely because of its superior product quality. Substantial number of revenue growth drivers including capturing market share, new product launches, and international expansion.
IH Financial details
IH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 2.91 | 4.83 | 11.75 | 17.72 | 0 | |
Net income per share | -0.39 | -6.09 | -0.83 | -0.69 | 0 | |
Operating cash flow per share | -0.1 | 0.94 | 4.93 | 0.72 | 0 | |
Free cash flow per share | -0.11 | 0.89 | 4.57 | 0.11 | 0 | |
Cash per share | 0.14 | 2.32 | 19.04 | 16.04 | 0 | |
Book value per share | -1.41 | -0.32 | 14.2 | 11.41 | 0 | |
Tangible book value per share | -1.41 | -0.32 | 13.94 | 10.9 | 0 | |
Share holders equity per share | -1.41 | -0.32 | 14.2 | 11.41 | 0 | |
Interest debt per share | 0 | -0.1 | -0.08 | 0.32 | 0 | |
Market cap | 4.98B | 5.05B | 5.35B | 951.44M | 4058.82B | |
Enterprise value | 4.98B | 4.94B | 4.49B | 130.33M | 4057.78B | |
P/E ratio | -283.02 | -18.31 | -142.75 | -25.68 | 36.96K | |
Price to sales ratio | 37.78 | 23.08 | 10.06 | 1.01 | 4.12K | |
POCF ratio | -1.11K | 118.37 | 23.99 | 24.9 | 21.54K | |
PFCF ratio | -989.91 | 125.41 | 25.83 | 160.42 | 22.32K | |
P/B Ratio | -78.17 | -349.22 | 8.32 | 1.56 | 5.27K | |
PTB ratio | -78.17 | -349.22 | 8.32 | 1.56 | 5.27K | |
EV to sales | 37.74 | 22.6 | 8.45 | 0.14 | 4.12K | |
Enterprise value over EBITDA | -318.39 | -17.76 | -101.12 | -2.4 | 36.37K | |
EV to operating cash flow | -1.1K | 115.91 | 20.16 | 3.41 | 21.53K | |
EV to free cash flow | -988.69 | 122.8 | 21.71 | 21.97 | 22.31K | |
Earnings yield | 0 | -0.05 | -0.01 | -0.04 | 0 | |
Free cash flow yield | 0 | 0.01 | 0.04 | 0.01 | 0 | |
Debt to equity | 0 | 0 | 0.01 | 0.06 | 0.01 | |
Debt to assets | 0 | 0 | 0.01 | 0.03 | 0.01 | |
Net debt to EBITDA | 0.39 | 0.38 | 19.24 | 15.14 | -9.33 | |
Current ratio | 0.47 | 0.89 | 2.56 | 2.1 | 2.23 | |
Interest coverage | 0 | 60.9 | 4.33 | 3.18 | -5.27 | |
Income quality | 0.26 | -0.15 | -5.95 | -1.03 | 1.72 | |
Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
Payout ratio | -0.62 | -0.01 | -1.76 | 0 | 0 | |
Sales general and administrative to revenue | 0.11 | 0.87 | 0.22 | 0.1 | 0.11 | |
Research and developement to revenue | 0.4 | 0.78 | 0.38 | 0.44 | 0.32 | |
Intangibles to total assets | 0 | 0 | 0.01 | 0.02 | 0.02 | |
Capex to operating cash flow | 0.12 | -0.06 | -0.07 | -0.84 | -0.03 | |
Capex to revenue | 0 | -0.01 | -0.03 | -0.03 | -0.01 | |
Capex to depreciation | -1.45 | -4.01 | -5.65 | -5.03 | -0.61 | |
Stock based compensation to revenue | 0 | 1.24 | 0.15 | 0.02 | 0.01 | |
Graham number | 3.51 | 6.61 | 16.26 | 13.35 | 0.01 | |
ROIC | -0.73 | 5.41 | 0.06 | 0.08 | -0.12 | |
Return on tangible assets | -0.3 | -1.64 | -0.04 | -0.03 | 0.08 | |
Graham Net | -2.01 | -1.14 | 11.59 | 7.9 | 0 | |
Working capital | -65.01M | -19.7M | 622.24M | 532.31M | 692.74M | |
Tangible asset value | -63.87M | -14.55M | 630.86M | 581.08M | 744.58M | |
Net current asset value | -65.01M | -19.7M | 617.17M | 522.73M | 689.84M | |
Invested capital | 0 | 0 | 0.01 | 0.06 | 0.01 | |
Average receivables | 0 | 17.3M | 49.64M | 68.63M | 70.44M | |
Average payables | 0 | 11.72M | 15.93M | 26.04M | 27.37M | |
Average inventory | 0 | 25.15M | 18.77M | 22.46M | 23.59M | |
Days sales outstanding | 37.71 | 35.03 | 53.72 | 22.79 | 30.33 | |
Days payables outstanding | 72.8 | 44.68 | 47.25 | 39.23 | 30.02 | |
Days of inventory on hand | 164.22 | 89.62 | 37 | 36.04 | 23.72 | |
Receivables turnover | 9.68 | 10.42 | 6.79 | 16.02 | 12.03 | |
Payables turnover | 5.01 | 8.17 | 7.72 | 9.3 | 12.16 | |
Inventory turnover | 2.22 | 4.07 | 9.87 | 10.13 | 15.39 | |
ROE | 0.28 | 19.07 | -0.06 | -0.06 | 0.14 | |
Capex per share | -0.01 | -0.05 | -0.35 | -0.61 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 4.46 | 4.54 | 4.33 | 4.72 | 4.9 | |
Net income per share | -0.15 | 0.25 | 0.41 | 0.74 | 0.67 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 3.56 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 3.52 | |
Cash per share | 16.04 | 14.85 | 16.06 | 17.84 | 19.73 | |
Book value per share | 11.41 | 11.56 | 12.54 | 13.89 | 14.46 | |
Tangible book value per share | 11.41 | 11.56 | 12.54 | 13.89 | 13.99 | |
Share holders equity per share | 11.41 | 11.56 | 12.54 | 13.89 | 14.46 | |
Interest debt per share | 0.59 | 0.47 | 0.28 | 0.08 | 0.07 | |
Market cap | 951.54M | 728.06M | 842.92M | 834.42M | 954.11M | |
Enterprise value | 130.43M | 38.58M | 152.34M | -30.5M | -86.87M | |
P/E ratio | -30.08 | 13.88 | 9.67 | 5.28 | 6.73 | |
Price to sales ratio | 4 | 3 | 3.66 | 3.32 | 3.66 | |
POCF ratio | 0 | 0 | 0 | 0 | 5.03 | |
PFCF ratio | 0 | 0 | 0 | 0 | 5.1 | |
P/B Ratio | 1.56 | 1.18 | 1.26 | 1.13 | 1.24 | |
PTB ratio | 1.56 | 1.18 | 1.26 | 1.13 | 1.24 | |
EV to sales | 0.55 | 0.16 | 0.66 | -0.12 | -0.33 | |
Enterprise value over EBITDA | -16.54 | 3.42 | 6.74 | -0.79 | -2.22 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | -0.46 | |
EV to free cash flow | 0 | 0 | 0 | 0 | -0.46 | |
Earnings yield | -0.01 | 0.02 | 0.03 | 0.05 | 0.04 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0.2 | |
Debt to equity | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | |
Debt to assets | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 104.15 | -61.05 | -30.54 | -22.44 | -26.6 | |
Current ratio | 2.1 | 2.1 | 2.27 | 2.37 | 2.23 | |
Interest coverage | 3.93 | -2.37 | -7.75 | -3.01 | -10.35 | |
Income quality | 0 | 0 | 0 | 0 | 1.97 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0.08 | |
Sales general and administrative to revenue | 0.13 | 0.11 | 0.13 | 0.1 | 0.11 | |
Research and developement to revenue | 0.46 | 0.4 | 0.34 | 0.29 | 0.26 | |
Intangibles to total assets | 0 | 0.03 | 0.03 | 0.02 | 0.02 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | -0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -0.24 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.05 | |
Graham number | 6.17 | 7.99 | 10.74 | 15.22 | 14.72 | |
ROIC | 0.02 | -0.02 | -0.06 | -0.04 | -0.06 | |
Return on tangible assets | -0.01 | 0.01 | 0.02 | 0.03 | 0.03 | |
Graham Net | 7.9 | 7.46 | 8.64 | 10.01 | 10.47 | |
Working capital | 532.31M | 517.53M | 581.65M | 658.16M | 692.74M | |
Tangible asset value | 608.37M | 590.74M | 640.34M | 712.52M | 744.58M | |
Net current asset value | 522.73M | 513.74M | 578.16M | 654.96M | 689.84M | |
Invested capital | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | |
Average receivables | 68.2M | 75.2M | 80.98M | 75.47M | 81.15M | |
Average payables | 33.7M | 27.67M | 22.17M | 16.72M | 19.06M | |
Average inventory | 26.45M | 26.2M | 24.26M | 20.34M | 17.82M | |
Days sales outstanding | 22.32 | 33.91 | 27.53 | 28.77 | 28.27 | |
Days payables outstanding | 37.69 | 30.67 | 26.07 | 16.82 | 27.33 | |
Days of inventory on hand | 34.63 | 30.1 | 32.26 | 19.98 | 21.6 | |
Receivables turnover | 4.03 | 2.65 | 3.27 | 3.13 | 3.18 | |
Payables turnover | 2.39 | 2.93 | 3.45 | 5.35 | 3.29 | |
Inventory turnover | 2.6 | 2.99 | 2.79 | 4.5 | 4.17 | |
ROE | -0.01 | 0.02 | 0.03 | 0.05 | 0.05 | |
Capex per share | 0 | 0 | 0 | 0 | -0.05 |
IH Frequently Asked Questions
What is iHuman Inc. stock symbol ?
iHuman Inc. is a CN stock and trading under the symbol IH
What is iHuman Inc. stock quote today ?
iHuman Inc. stock price is $2.96 today.
Is iHuman Inc. stock public?
Yes, iHuman Inc. is a publicly traded company.